Last updated: August 1, 2026
Sulfapyridine is an older sulfonamide antibacterial that no longer has a meaningful standalone commercial market in the United States. Current clinical activity is concentrated in related products, especially sulfasalazine, which is metabolized in the colon to sulfapyridine and 5-aminosalicylic acid. No active development program has established sulfapyridine as a modern antibacterial, immunomodulatory, or inflammatory-disease product. Its commercial outlook is limited to niche compounded use, historical formulations, and indirect exposure through sulfasalazine.
What is sulfapyridine and how is it used?
Sulfapyridine is a sulfonamide antimicrobial with historical activity against susceptible gram-positive and gram-negative bacteria. Its clinical use declined because of resistance, hypersensitivity reactions, hematologic toxicity, and the availability of newer antibiotics.
Its current clinical relevance comes from three areas:
| Area |
Current relevance |
| Direct antibacterial therapy |
Limited and largely historical |
| Dermatologic disease |
Historical use in dermatitis herpetiformis and related neutrophilic disorders |
| Sulfasalazine metabolism |
Sulfapyridine is one of sulfasalazine's active metabolites |
Sulfasalazine remains approved in the United States for rheumatoid arthritis and ulcerative colitis. The sulfapyridine component is released by bacterial azoreduction in the colon. The pharmacologic effect of sulfasalazine depends on both sulfapyridine and 5-aminosalicylic acid, although their relative contributions vary by indication and patient.
Sulfapyridine should not be treated as interchangeable with sulfasalazine. Sulfasalazine is the approved drug product; sulfapyridine is a metabolite and, in limited settings, a separately compounded or historically marketed active ingredient.
What clinical trials are evaluating sulfapyridine?
No significant modern clinical-trial pipeline is centered on sulfapyridine as a standalone investigational product. ClinicalTrials.gov activity involving the compound is generally linked to sulfasalazine, historical treatment protocols, or observational work involving adverse effects and drug metabolism rather than a new sulfapyridine therapy program.[1]
Current clinical-trial position
| Development category |
Status |
| Standalone sulfapyridine antibacterial trials |
No meaningful active development program identified |
| New sulfapyridine formulation trials |
No established late-stage program |
| Sulfasalazine trials involving sulfapyridine exposure |
Ongoing or historical depending on indication |
| Dermatology trials |
Modern studies generally favor dapsone or other therapies |
| Antimicrobial development |
No credible commercial repositioning program |
Modern research involving sulfapyridine is more likely to examine pharmacogenetics, sulfasalazine tolerability, intestinal metabolism, or adverse events. The principal safety concerns include hypersensitivity, agranulocytosis, hemolysis in susceptible patients, hepatotoxicity, and crystalluria.
How does sulfapyridine compare with dapsone in dermatitis herpetiformis?
Dapsone is the established systemic treatment for dermatitis herpetiformis. Sulfapyridine has historical value but is generally less commercially relevant and less commonly used. Dapsone also carries clinically important risks, including hemolysis and methemoglobinemia, particularly in patients with glucose-6-phosphate dehydrogenase deficiency.
| Attribute |
Sulfapyridine |
Dapsone |
| Current dermatology role |
Niche or historical |
Established systemic option |
| Regulatory footprint |
Limited |
Broader |
| Commercial availability |
Often compounded or limited |
Commercially available in multiple markets |
| Main safety concerns |
Sulfonamide hypersensitivity, blood dyscrasias, hepatic toxicity |
Hemolysis, methemoglobinemia, hypersensitivity |
| Clinical-trial activity |
Minimal |
Greater, although still limited for a rare disease |
What is the FDA regulatory status of sulfapyridine?
Sulfapyridine does not have a substantial current FDA-approved standalone product presence comparable to sulfasalazine or dapsone. The FDA-approved product with direct commercial relevance is sulfasalazine, marketed in immediate-release and delayed-release forms by multiple manufacturers.[2]
The regulatory distinction is material:
- Sulfapyridine is a metabolite of sulfasalazine.
- Sulfasalazine has approved labeling for ulcerative colitis and rheumatoid arthritis.
- A sulfapyridine compound would require its own regulatory basis if marketed as a new drug.
- Compounded products do not create the same approval, exclusivity, or labeling position as an FDA-approved commercial product.
What is the Orange Book status of sulfapyridine?
Sulfapyridine has no commercially important current Orange Book patent position. No active standalone Orange Book estate is associated with a major branded sulfapyridine product.
Sulfasalazine products may appear in FDA product databases, but that does not establish patent protection for sulfapyridine itself. Most original composition, formulation, and use patents covering sulfasalazine are expired or commercially weak because the product has been marketed for decades.[3]
Orange Book and exclusivity assessment
| Issue |
Assessment |
| Standalone sulfapyridine listing |
No meaningful current listing |
| Active new chemical entity exclusivity |
None |
| Current orphan exclusivity |
None identified |
| Pediatric exclusivity |
None identified |
| Active patent estate |
No material standalone estate |
| Paragraph IV exposure |
No major current sulfapyridine dispute identified |
What patents protect sulfapyridine?
The original composition-of-matter protection for sulfapyridine expired many decades ago. The compound was discovered and commercialized before the modern Hatch-Waxman framework, and no active composition patent can provide meaningful exclusivity today.
Potentially relevant historical or secondary rights could have covered:
- Sulfasalazine formulations
- Delayed-release tablets
- Combination or conjugate chemistry
- Manufacturing processes
- Specific inflammatory or gastrointestinal indications
- Analytical methods and impurity controls
Those categories do not create a meaningful current barrier to sulfapyridine entry. Any modern commercial opportunity would depend on regulatory execution, formulation differentiation, supply quality, and clinical positioning rather than basic compound patent protection.
When does sulfapyridine lose exclusivity?
Sulfapyridine lost practical exclusivity decades ago. There is no current exclusivity cliff comparable to the expected loss of protection for a recently launched branded medicine.
| Protection type |
Estimated position |
| Original compound patent |
Expired |
| New chemical entity exclusivity |
Expired or unavailable |
| Standalone formulation exclusivity |
No material current protection |
| Method-of-use exclusivity |
No commercially significant current position |
| Regulatory market exclusivity |
None identified |
The relevant commercial question is therefore not when sulfapyridine loses exclusivity. It is whether any manufacturer can create a viable approved or compounded product despite limited demand and the availability of alternatives.
Are there Paragraph IV challenges or litigation involving sulfapyridine?
No major current Paragraph IV litigation involving a standalone sulfapyridine product is evident in the principal U.S. generic-drug litigation landscape. The compound's age and limited commercial use reduce the incentive for branded-versus-generic litigation.
Litigation risk is more likely to arise from:
- Product-liability claims involving sulfonamide hypersensitivity
- Compounding quality or contamination
- Mislabeling of sulfapyridine-containing products
- Sulfasalazine manufacturing or bioequivalence disputes
- Patent disputes involving a new formulation rather than the old active ingredient
No current settlement agreement is a material determinant of sulfapyridine market entry.
What is the sulfapyridine market size and commercial outlook?
There is no established public market consensus for standalone sulfapyridine revenue. Major pharmaceutical market reports generally group the compound into broader sulfonamide, dermatology, antimicrobial, compounded-medicine, or sulfasalazine categories.
The standalone market is best characterized as small and fragmented:
| Segment |
Commercial outlook |
| Direct oral sulfapyridine products |
Minimal |
| Compounded dermatology use |
Small niche |
| Veterinary or specialty use |
Possible but limited |
| Sulfasalazine-related exposure |
Commercially relevant only at the parent-product level |
| New branded sulfapyridine |
Low probability without a differentiated indication |
Five-year projection
A standalone sulfapyridine market is likely to remain flat to declining in conventional pharmaceutical channels. Growth would require one of four events:
- A new approved formulation with a clear safety or delivery advantage.
- Repositioning in a disease with inadequate treatment options.
- A validated role in antibiotic-resistant infection.
- Expansion of pharmacy-compounding demand supported by clinical guidelines.
None of these catalysts has produced a visible late-stage development program. The base case is continued niche use with low revenue concentration and no meaningful branded-price premium.
What generic entry risks exist for sulfapyridine?
Generic entry risk is structurally high because the active ingredient is old, chemically simple, and not protected by a significant current patent estate. The commercial constraint is demand rather than access to intellectual property.
A manufacturer would still face several barriers:
- Limited and unpredictable prescribing volume
- Need for validated raw-material supply
- Sulfonamide safety monitoring
- Potential difficulty obtaining a commercially attractive FDA pathway
- Competition from dapsone, sulfasalazine, corticosteroids, and newer immunomodulators
- Limited reimbursement leverage
- Small market size relative to development and compliance costs
For compounded products, the central barriers are quality control, pharmacy capability, physician familiarity, and patient demand rather than patent exclusivity.
How strong is the sulfapyridine patent estate?
The patent estate is weak from a current commercial perspective.
| Patent-strength factor |
Assessment |
| Composition patents |
Expired |
| Formulation patents |
No material standalone protection |
| Method-of-use patents |
Limited practical relevance |
| Manufacturing patents |
Potentially useful only for a differentiated process |
| Regulatory exclusivity |
None identified |
| Litigation leverage |
Low |
| Freedom-to-operate risk |
Generally low for the old compound, subject to product-specific review |
A new sulfapyridine product could still obtain patents on a novel dosage form, controlled-release system, combination, impurity profile, or manufacturing process. Those rights would protect the new technology, not the underlying molecule broadly.
How does sulfapyridine compare with sulfasalazine and dapsone?
| Factor |
Sulfapyridine |
Sulfasalazine |
Dapsone |
| Primary role |
Historical antimicrobial and niche dermatology use |
Approved inflammatory and gastrointestinal therapy |
Dermatology and infectious-disease uses |
| Standalone FDA commercial position |
Limited |
Established |
Established in several markets |
| Patent value |
Negligible |
Mostly expired legacy rights |
Mature, generally limited |
| Clinical activity |
Minimal |
Ongoing disease-management research |
Ongoing niche clinical use |
| Market opportunity |
Small |
Established generic market |
Specialty generic market |
| Main commercial risk |
Low demand |
Generic price pressure |
Safety monitoring and competition |
Sulfasalazine has the strongest commercial position because it has approved indications and a larger installed patient base. Dapsone has greater relevance in dermatology. Sulfapyridine remains the weakest standalone commercial opportunity.
Key Takeaways
- Sulfapyridine has no meaningful modern standalone clinical-trial pipeline.
- Its principal current relevance is as a metabolite of sulfasalazine.
- The original compound patent and practical exclusivity expired decades ago.
- No material current Orange Book, Paragraph IV, or settlement issue controls the market.
- Standalone sulfapyridine revenue is niche, fragmented, and not covered by a reliable public market consensus.
- The five-year outlook is flat to declining unless a differentiated formulation or new indication emerges.
- Sulfasalazine and dapsone have stronger clinical and commercial positions.
- Manufacturing and regulatory execution matter more than intellectual-property barriers.
FAQs About Sulfapyridine
Is sulfapyridine still FDA approved?
Sulfapyridine does not have a major current standalone FDA-approved commercial position. Sulfasalazine, which releases sulfapyridine in the colon, remains FDA approved.
Is sulfapyridine the same as sulfasalazine?
No. Sulfapyridine is one active metabolite of sulfasalazine. Sulfasalazine also produces 5-aminosalicylic acid and is the approved drug product.
Can sulfapyridine be used instead of dapsone?
Sulfapyridine has historical use in dermatitis herpetiformis, but dapsone is the more established systemic treatment. Substitution depends on clinical judgment, safety factors, and product availability.
Does sulfapyridine have antibiotic market potential?
The commercial potential is low. Resistance, toxicity, limited modern clinical evidence, and competition from newer antibiotics restrict the prospect of a standalone antibacterial product.
Are there active sulfapyridine patents?
No material active patent estate protects the old sulfapyridine molecule itself. New patents could protect a novel formulation, combination, manufacturing process, or therapeutic use.
References
- National Library of Medicine. (2024). ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
